Novel drug target linked to insulin secretion and type 2 diabetes treatment

A signal that promotes insulin secretion and reduces hyperglycemia in a type 2 diabetes animal model is enhanced by the inhibition of a novel enzyme discovered by CHUM Research Centre (CRCHUM) and University of Montreal researchers. The team is part of the Montreal Diabetes Research Center and their study, published recently in Cell Metabolism, was directed by researchers Marc Prentki and Murthy Madiraju.

Insulin is an important hormone in our body that controls glucose and fat utilization. Insufficient by the beta-cells of the pancreas and interference with the action of lead to type 2 diabetes. The secretion in the blood of insulin is dependent upon the utilization of glucose and fat by the beta-cells and the production of a novel signal that they discovered named monoacylglycerol.

"Despite significant research on the mechanisms implicated in insulin secretion, the signal molecules involved in this process remained enigmatic; the identification of these signals is necessary to develop better therapeutics against diabetes," explains Marc Prentki, Director of the Montreal Diabetes Research Centre and Professor at the University of Montreal. Marc Prentki holds the Canada Research Chair in Diabetes and Metabolism.

"When sugar is being used by the insulin secreting pancreatic beta-cell, it produces monoacylglycerol, a fat-like signal and this is associated with insulin release into blood; we found that the production of monoacylglycerol is essential for glucose-stimulated by the beta-cell," says Murthy Madiraju, Researcher at the CRCHUM.

Importantly, the research team discovered that an enzyme called alpha/beta hydrolase domain-6 (in short ABHD6) breaks down monoacylglycerol and thus negatively controls insulin release. These researchers said that "an ideal drug for type-2 diabetes would increase in blood by enhancing the beta cells response to glucose only when it is elevated and also increase the sensitivity of body tissues to insulin; this is precisely what ABHD6 inhibition does and thus we have identified a unique new target for type 2 diabetes."

The research team is currently in the process of discovering new and potent blockers of ABHD6 that do not show any unwanted toxicity and which can be developed as potential drugs for type 2 . These studies are being done in collaboration with AmorChem Financial, Inc., and its subsidiary NuChem Therapeutics, Montreal.

More information: Paper: http://www.cell.com/cell-metabolism/abstract/S1550-4131(14)00166-1

add to favorites email to friend print save as pdf

Related Stories

Loss of function of a single gene linked to diabetes in mice

Jan 04, 2014

Researchers from the University of Illinois at Chicago College of Medicine have found that dysfunction in a single gene in mice causes fasting hyperglycemia, one of the major symptoms of type 2 diabetes. Their findings were ...

How fat could help solve part of the diabetes problem

Oct 29, 2013

The pancreas is a large organ that wraps around our gut, and produces the exact amount of insulin our bodies need when we eat – except when we start to develop diabetes, and insulin production slows down. ...

Insulin secretion disrupted by increased fatty acids

Sep 09, 2013

Patients with type 2 diabetes have increased levels of circulating glucose and fatty acids, which lead to disease complications. In healthy individuals, β cells within pancreatic islets release insulin in response to glucose ...

Researchers find new pathway connected to type 2 diabetes

Mar 19, 2014

Scientists at the Children's Hospital of Eastern Ontario (CHEO) Research Institute have discovered a cellular pathway that is responsible for keeping blood sugar levels low in obese or pre-diabetic people, and may prevent ...

Recommended for you

Low-carb diet recommended for diabetics

Jul 29, 2014

A new study involving researchers from the University of Alabama at Birmingham and other institutions says patients with Type 1 and Type 2 diabetes should eat a diet low in carbohydrates.

Shift work linked to heightened risk of type 2 diabetes

Jul 24, 2014

Shift work is linked to a heightened risk of developing type 2 diabetes, with the risk seemingly greatest among men and those working rotating shift patterns, indicates an analysis of the available evidence published online ...

Rosemary and oregano contain diabetes-fighting compounds

Jul 23, 2014

The popular culinary herbs oregano and rosemary are packed with healthful compounds, and now lab tests show they could work in much the same way as prescription anti-diabetic medication, scientists report. In their new study ...

User comments